nivolumab,ipilimumab
bms
['cm914', 'nivo', ' ipi ']
presidential-2 #esmo22 primary endpoint for phase 3 cm914 trial not met, nivo + ipi not superior to placebo--higher toxicity. no clear subgroups that benefit. part-b: adjuvant nivo only is ongoing! 
Cancer researcher; Director of GU Cancers @DanaFarber; Prof of Medicine @HarvardMed; ? lover; ??@PanMass
Views are mine.